

Cancer Clinical Trials at Virginia Mason Medical Center



This list represents the clinical trials in cancer treatment and cancer control approved by the Benaroya Research Institute Institutional Review Board for use within Virginia Mason Medical Center, and with CCOP, RTOG, CTU, and CCRU participants. For more information please call or email us, or visit ClinicalTrials.gov and enter the National Cancer Institute ID; there you will find study schema, objectives, eligibility criteria and more.

Cancer Control/Symptom Prevention

A Study of the Effects of Exercise on Cancer-Related Fatigue | Study IDs: URCC 08106, NCT00924651 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/EVER/FAIR/PACMED/VALY

A Phase III, Randomized, Placebo-controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes | Study IDs: NCCTG N08C7, NCT00956813 | PI: Jacqueline Vuky, CRC: Erika Douglass | Sites: VMMC/EVER/FAIR/PACMED/VALY

Randomized Placebo-controlled Trial of Acetyl-L-Carnitine (ALC) For the Prevention of Taxane Induced Neuropathy, Phase III | Study IDs: SWOG S0715, NCT00775645 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/EVER/FAIR/PACMED/VALY

Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men with Prostate Cancer | Study IDs: IRB09061, NCT00354432 | PI: Jacqueline Vuky, CRC: Andrea Jacks | Sites: VMMC/EVER/FAIR/PACMED/VALY

Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases | Study IDs: SWOG S0702, NCT00874211 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/EVER/FAIR/PACMED/VALY

The Use of Wisconsin Ginseng (*panax quinquefolius*) to Improve Cancer Related fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study | Study IDs: NCCTG N07C2, NCT00719563 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/EVER/FAIR/PACMED/VALY

Assessment of Topical Treatment Response with Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN) | Study IDs: URCC U07004, NCT00471445 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/EVER/FAIR/PACMED/VALY

Paclitaxel-Associated Acute Pain Syndrome Natural History Study | Study IDs: NCCTG N08C1, NCT00860041 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/EVER/FAIR/PACMED/STF/VALY

Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer | Study IDs: RTOG 0517, NCT00365105 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/FAIR/STF

A Randomized Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy | Study IDs: RTOG 0614, NCT00566852 | PI: Huong Pham, CRC: Erica Swenson | Sites: VMMC/FAIR/PACMED/STF

Bladder

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | Study IDs: RTOG 0524, NCT00238420 | PI: Huong Pham, CRC: Kathy Rabena | Sites: VMMC/EVER/PACMED/STF

Brain

Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate and High-Risk Meningiomas | Study IDs: RTOG 0539, NCT00895622 | PI: Huong Pham, CRC: Kathy Rabena | Sites: VMMC/STF

Phase III Double-blind Placebo-controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma | Study IDs: RTOG 0825, NCT00884741 | PI: Lynne Taylor, CRC: Kathy Rabena | Sites: VMMC/EVER/PACMED/STF

Phase I/II Trial of BIBW 2992 in Treating Patients With Recurrent Glioblastoma Multiforme | Study IDs: IRB08136 / 3057000, NCT00727506 | PI: Lynne Taylor, CRC: Leslie Stevens | Sites:

Breast

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy | Study IDs: NSABP B-43, NCT00769379 | PI: Jacqueline Vuky, CRC: Kathy Rabena | Sites: VMMC/EVER/FAIR/PACMED/VALY

Image Guided Partial Breast Irradiation | Study IDs: BRI 3031600, NCT00749437 | PI: Huong Pham, CRC: Erica Swenson | Sites: VMMC

The TAILORx Study: using gene expression as guide for treatment | Study IDs: ECOG PACCT-1 / TAILORx, NCT00310180 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/EVER/FAIR/PACMED/VALY

Treatment With Pazopanib for Neoadjuvant Breast Cancer | Study IDs: IRB09008, NCT00849472 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC

LPT 111111- Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel and Lapatinib in Women With No More Than One Prior Treatment for ERBB2 Overexpressing Metastatic Breast Cancer | Study IDs: BRI 3055900, NCT00709761 | PI: Jacqueline Vuky, CRC: Leila Ponce | Sites: VMMC

Colorectal

Preop Radiation Therapy & Capecitabine w/ or w/o Oxaliplatin w/ Preop Radiation Therapy & Continuous Intravenous Infusion of 5-FU w/ or w/o Oxaliplatin in the Tx of Pts w/Operable Carcinoma of the Rectum | Study IDs: NSABP R-04, NCT00058474 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/EVER/FAIR/PACMED/VALY

Esophageal

A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus | Study IDs: ACOSOG Z4051 / IRB09039, NCT00757172 | PI: Richard Thirlby, CRC: Leila Ponce | Sites: VMMC

Head and Neck

A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck | Study IDs: RTOG 0619, NCT00720083 | PI: Huong Pham, CRC: Erica Swenson | Sites: VMMC/STF

A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer | Study IDs: ECOG E1305, NCT00588770 | PI: Jacqueline Vuky, CRC: Erica Swenson | Sites: VMMC/EVER/FAIR/PACMED/PROV/VALY

HIV/AIDS Malignancy

A Phase I/Pharmacokinetic Study of Sunitinib in Patients with Cancer who also have HIV and are on HAART Therapy | Study IDs: AMC-061 / IRB09072, NCT00890747 | PI: David Aboulafia, CRC: Leila Ponce | Sites: VMMC

A Companion Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamous Intraepithelial Lesions (ASIL) in Subjects Participating in AMC Clinical Trials | Study IDs: AMC-058 / IRB09053, NCT00695422 | PI: David Aboulafia, CRC: Leila Ponce | Sites: VMMC

Phase II Trial of Combined Modality Therapy plus Cetuximab in HIV-Associated Anal Carcinoma | Study IDs: AMC-045 / IRB06082, NCT00324415 | PI: David Aboulafia, CRC: Leila Ponce | Sites: VMMC

Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) including CNS Penetration & Intensive IT Prophylaxis in HIV-Associated Burkitt's & Atypical Burkitt's Lymphoma | Study IDs: AMC-048 / IRB08004 / 3021700, NCT00392834 | PI: David Aboulafia, CRC: Leila Ponce | Sites: VMMC

A Phase 1/2 Trial of PTC299 in Patients with HIV-Related Kaposi's Sarcoma | Study IDs: AMC-059 / IRB09001, NCT00686842 | PI: David Aboulafia, CRC: Leila Ponce | Sites: VMMC

Kidney

ASSURE: Adjuvant Sunitinib or Sorafenib for unfavorable renal cell carcinoma (double-blind study) | Study IDs: ECOG E2805, NCT00326898 | PI: Jacqueline Vuky, CRC: Erika Douglass | Sites: VMMC/EVER/FAIR/PACMED/VALY

Phase 3b Randomized Open-Label Study of Bevacizumab + Temezirolimus (Arm A) vs. Bevacizumab + Interferon-Alpha (Arm B) as First-Line Treatment for Subjects with Advanced RCC | Study IDs: BRI 3051950, NCT00631371 | PI: Jacqueline Vuky, CRC: Andrea Jacks | Sites: VMMC

A Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma | Study IDs: IRB08074, NCT00720941 | PI: Jacqueline Vuky, CRC: Andrea Jacks | Sites: VMMC

Randomized, Double-Blind Phase 2 Study of Axitinib with or without Dose Titration in Patients with mRCC | Study IDs: IRB09024, NCT00835978 | PI: Jacqueline Vuky, CRC: Andrea Jacks | Sites: VMMC

Axitinib (AG-013736) as Second Line Therapy for Metastatic Renal Cell Cancer: The Axis Trial | Study IDs: IRB08052 / BRI 3053200, NCT00678392 | PI: Jacqueline Vuky, CRC: Andrea Jacks | Sites: VMMC

Leukemia and Lymphoma

A Phase II Study of Bexxar Consolidation in Patients with B-Cell Chronic Lymphocytic Leukemia Following Fludarabine and Rituximab Chemotherapy | Study IDs: PSOC 2301, NCT00476047 | PI: John Pagel, CRC: Britt Kammerer | Sites: FHCRC

A Phase I/II Study of Vorinostat plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients with Relapsed or Refractory Lymphoid Malignancies (Including B-cell, T-cell, or Hodgkin 's disease) | Study IDs: PSOC 2302, NCT00601718 | PI: L. Elizabeth Budde, CRC: Britt Kammerer | Sites: FHCRC

A Phase I/II Study of Fludarabine (F), Cyclophosphamide (C), Rituximab (R), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Study IDs: PSOC 2401, NCT00918723 | PI: John Pagel, CRC: Britt Kammerer | Sites: FHCRC

Liver

A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation | Study IDs: IRB08070, NCT00692770 | PI: Thomas Malpass, CRC: Andrea Jacks | Sites: VMMC

A Phase II randomized, double-blind, placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolisation (TACE) for hepatocellular carcinoma | Study IDs: IRB08141, NCT00855218 | PI: Thomas Malpass, CRC: Andrea Jacks | Sites: VMMC

A Multinational, Randomized, Open-label Phase 3 Study of Sunitinib Malate versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma | Study IDs: BRI 3054800, NCT00699374 | PI: Thomas Malpass, CRC: Andrea Jacks | Sites: VMMC

Lung

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC) | Study IDs: ECOG E1505, NCT00324805 | PI: Jacqueline Vuky, CRC: Kathy Rabena | Sites: VMMC/EVER/FAIR/PACMED/VALY

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | Study IDs: RTOG 0617 / IRB08058, NCT00533949 | PI: Huong Pham, CRC: Kathy Rabena | Sites: VMMC

Neuroendocrine

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients | Study IDs: SWOG S0518, NCT00569127 | PI: Jacqueline Vuky, CRC: Kathy Rabena | Sites: VMMC/EVER/FAIR/PACMED/VALY

Pancreatic

A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer | Study IDs: GV-001.004, NCT00051467 | PI: Andrew Ross, CRC: Jody Mooney | Sites:

Prostate

A Randomized, Double-Blinded, Placebo-Controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer | Study IDs: RTOG 0831 / IRB10003, NCT00931528 | PI: Huong Pham, CRC: Erica Swenson | Sites: VMMC/FAIR/STF

START - A Phase III Study of Active Surveillance Therapy v. Radical Treatment in Patients Diagnosed with Favorable Risk Prostate Cancer | Study IDs: NCIC CTG PR.11, NCT00499174 | PI: John Corman, CRC: Erika Douglass | Sites: VMMC/EVER/FAIR/PACMED/PROV/VALY

An Open label, Phase 2 Trial of Immunotherapy with Sipuleucel-T (Provenge®) as Neoadjuvant Treatment in Men with Localized Prostate Cancer | Study IDs: IRB08128, NCT00715104 | PI: John Corman, CRC: Kathryn Dahl | Sites: VMMC

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer | Study IDs: RTOG 0815, NCT00936390 | PI: Huong Pham, CRC: Erica Swenson | Sites: VMMC/PACMED/STF

Phase II Study of Neoadjuvant IMC-A12 combined with Androgen Deprivation Prior to Prostatectomy | Study IDs: IRB08078, NCT00769795 | PI: John Corman, CRC: Erin Odom | Sites: VMMC

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer | Study IDs: CALGB 90203, NCT00430183 | PI: Jacqueline Vuky, CRC: Erika Douglass | Sites: VMMC/EVER/FAIR/PACMED/PROV/VALY

Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial | Study IDs: RTOG 0621, NCT00528866 | PI: Huong Pham, CRC: Erica Swenson | Sites: VMMC/EVER/PACMED/STF

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy | Study IDs: RTOG 0534, NCT00567580 | PI: Huong Pham, CRC: Erica Swenson | Sites: VMMC/STF

Randomized Trial of ChemoHormonal Tx vs. Androgen Ablation for Extensive Disease in Prostate Ca | Study IDs: ECOG E3805, IRB09009, NCT00309985 | PI: Jacqueline Vuky, CRC: Erika Douglass | Sites: VMMC/EVER/FAIR/PACMED/VALY

Phase III Study of Docetaxel and Atrasetan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer | Study IDs: SWOG S0421, NCT00134056 | PI: Jacqueline Vuky, CRC: Erika Douglass | Sites: VMMC/EVER/FAIR/PACMED/VALY

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancer | Study IDs: IRB07106, NCT00617669 | PI: John Corman, CRC: Erin Odom | Sites: VMMC

A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus in Men with Asymptomatic, Metastatic Castrate-Resistant Prostate Cancer | Study IDs: IRB08096, NCT00777959 | PI: John Corman, CRC: Kathryn Dahl | Sites: VMMC

A Randomized, Multicenter, Single Blind Study in Men with Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen | Study IDs: IRB09044, NCT00715078 | PI: John Corman, CRC: Kathryn Dahl | Sites: VMMC

Solid Tumors

Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study | Study IDs: IRB09016, | PI: Kas Badiozamani, CRC: Leila Ponce | Sites: VMMC